Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 12:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Methamphetamine Use Disorder, Transcranial Magnetic Stimulation
Interventions
Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Active, Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Sham
Device
Lead sponsor
Stanford University
Other
Eligibility
25 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Dex +/- Caffeine Sedation in a Post-MRI Recovery in a Pediatric Population

NCT06538584
Conditions
Enhanced Recovery After Surgery in a Pediatric Population
Interventions
Caffeine citrate 15mg/kg, 0.9% Sodium Citrate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
3 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
ADHD
Interventions
Stimulant Diversion Prevention (SDP)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
13 Years to 18 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age

NCT01206478
Conditions
Chronic Oral Food Refusal
Interventions
Amitriptyline, Placebo, Megestrol
Drug
Lead sponsor
Ann Davis, PhD, MPH, ABPP
Other
Eligibility
9 Months to 8 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
3
States / cities
Kansas City, Kansas • New Orleans, Louisiana • Columbus, Ohio
Conditions
Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Interventions
Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
25 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Conditions
Post-traumatic Stress Disorder (PTSD), Post-traumatic Stress Symptoms, Opioid Use Disorder (OUD), Stimulant Use Disorder, Stimulant Use & Co-occuring Opioid Use Disorders, Co-occurring Mental and Substance Use Disorders, Medications for Opioid Use Disorder
Interventions
Cognitive Processing Therapy (CPT), Written Exposure Therapy (WET)
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Little Rock, Arkansas
Conditions
Opioid Use Disorder, Injection Related Infections, Stimulant Use Disorder
Interventions
Integrated Infectious Diseases and Substance Use Disorder Clinic (IC)
Behavioral
Lead sponsor
Elana Rosenthal
Other
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Baltimore, Maryland + 1 more
Conditions
Amphetamine-Related Disorders, Tobacco Use Disorder
Interventions
radioactive substance
Procedure
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions
Solriamfetol 150 MG, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Tucson, Arizona • Bellflower, California • Chino, California + 33 more
Conditions
Binge-Eating Disorder
Interventions
Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Encino, California • Garden Grove, California • Long Beach, California + 38 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Abuse Potential of Istradefylline

NCT02609477
Conditions
Drug Abuse
Interventions
Istradefylline, Phentermine 45 mg, Placebo
Drug · Other
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD

NCT03103750
Conditions
ADHD
Interventions
Magnetic Resonance Imaging (MRI), PHNO, calcitriol, Placebo oral capsule, high-resolution research tomography, Dextro Amphetamine
Procedure · Drug · Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Stimulant Use Disorder, People Living With HIV
Interventions
reSET, Standard of care
Behavioral · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Miami, Florida
Conditions
Mood Disorder, Mental Disorder Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Add-on citalopram following optimized methylphenidate, Add-on placebo following optimized methylphenidate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Sleep Disorder, Healthy
Interventions
Sleep Fragmentation, Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo), Sleep Continuity Disruption, Undisturbed Sleep
Behavioral · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 48 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Long-Duration Stimulant Treatment Study of ADHD in Young Children

NCT00257725
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
B-MPH
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
4 Years to 5 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Completed Phase 1 Interventional Accepts healthy volunteers

Study for Naltrexone on the Abuse Potential of Methylphenidate

NCT03769064
Conditions
Naltrexone, Methylphenidate Abuse
Interventions
Placebo, Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134, Treatment Phase Sequence 1342, Treatment Phase Sequence 3421
Drug
Lead sponsor
Avekshan LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
HIV (Human Immunodeficiency Virus)
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 1 more
Conditions
Opioid Use Disorder, Overdose, Drug, Overdose, Substance Use (Drugs, Alcohol)
Interventions
Community Paramedic Standard of Care (CP SOC), CROSSROADS
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • Durham, North Carolina + 1 more
Completed No phase listed Observational

Kentucky Access to Recovery Evaluation

NCT05889702
Conditions
Substance Use Disorders, Treatment Adherence and Compliance
Interventions
KATR Linkage Strategy
Behavioral
Lead sponsor
Terry Bunn
Other
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Berea, Kentucky • Lexington, Kentucky
Completed No phase listed Observational

Stimulant Use and Methylation in HIV

NCT05916989
Conditions
HIV Infections, Methamphetamine-dependence, Methamphetamine Abuse
Interventions
Not listed
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Miami, Florida
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
SMS Intervention
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

Pharmacogenetics of Naltrexone for Stimulant Abuse

NCT03226223
Conditions
Substance Use Disorders, Methamphetamine Abuse
Interventions
Intranasal Methamphetamine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Stimulant Use (Diagnosis), Hiv
Interventions
Contingency management
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California